Yes. In the two most direct human studies on the question — one measuring NAD+ in skin tissue, one in blood plasma — researchers found levels fall steadily as people get older, with one reporting a strong, statistically significant decline (a correlation of r = -0.71 in men and r = -0.54 in women) stretching from the teenage years into the 70s.¹
In brief:
- Two independently designed studies, measuring two different tissues — skin and blood plasma — both found the same pattern: NAD+ levels fall as people age.
- The decline is a strong statistical association, not proof that low NAD+ causes aging or that restoring it reverses anything.
- What raising NAD+ levels does for a healthy adult — more energy, slower aging, or nothing measurable at all — is still an open research question, not an established outcome.
What is NAD+, and why would its level matter?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell in your body. Its best-understood job is in energy metabolism: it shuttles electrons through the chemical reactions that convert food into usable cellular energy. It also serves as the raw material for a DNA-repair enzyme called PARP and for the sirtuin family of enzymes that regulate gene activity — both processes that researchers studying aging have focused on closely, because both consume NAD+ to run.¹
That's the mechanistic reason level matters at all: if NAD+ supply drops while the demand from DNA repair and cellular signaling stays the same or rises, cells may have less of the coenzyme available for the metabolic work it's needed for. Whether that mechanism actually plays out that way in a living person, and what it means for their health, is a separate and much harder question than simply measuring the level itself.
What did researchers find in skin tissue?
The most frequently cited direct measurement comes from a 2012 study that analyzed pelvic skin samples from 49 people ranging from newborns to age 77.¹ The researchers found a strong negative correlation between NAD+ levels and age in both men (r = -0.706) and women (r = -0.537) — in plain terms, the older the sample, the lower the NAD+, consistently enough to be statistically significant in a sample that size. The same tissue also showed rising DNA damage with age, and rising activity of PARP, the NAD+-consuming repair enzyme, which inversely tracked with NAD+ levels — a pattern the authors interpreted as PARP's repair work using up NAD+ faster than the body replaces it as people age.
Does the same pattern show up in blood?
A second study, published in 2019, took a different approach: instead of a tissue biopsy, researchers measured NAD+ and related metabolites directly in blood plasma from healthy adults aged 20 to 87, using mass spectrometry.² They found a significant decline in plasma NAD+ and a related metabolite, NADP+, with age — while some of the breakdown products NAD+ turns into after it's used (including NADH and nicotinamide) actually rose with age. That combination suggests the shift isn't simply "less NAD+ coming in" — it may also reflect a change in how quickly the body cycles through the NAD+ it has.
Measuring a second tissue mattered because skin and blood don't necessarily tell the same story. Skin is easy to sample, which is why it's a common choice for this kind of study, but it's one tissue among many — it doesn't tell you what's happening in muscle, liver, or brain, where NAD+ is also used. Blood plasma is more practical to sample repeatedly and reflects what's circulating in the body generally, but it's still a proxy for what's going on inside individual organs, not a direct window into them. Finding the same downward direction in two different, independently collected sample types is one of the reasons this particular pattern is considered reasonably well established, even though each individual study has the limits of its own tissue type. Neither study measured the same people over time, either; each compared different people of different ages at a single point, which is the standard design for this kind of question but a meaningfully different thing from tracking one person's own NAD+ as they age.
So does this mean raising NAD+ reverses aging?
No study has shown that. Both the skin-tissue and blood-plasma findings are cross-sectional associations — they show that older people, on average, measured lower than younger people at one point in time. Neither study tested what happens if you raise someone's NAD+ level, so neither one can say whether doing so slows, reverses, or has no effect on how a person ages. The kind of study that could actually answer that question is a randomized trial that raises NAD+ in one group, gives a placebo to another, and compares a specific, predefined health outcome between the two over time — a different and more demanding design than measuring who has more or less of it at a single age. That gap between "levels decline with age" and "replacing it reverses aging" is exactly where a lot of consumer marketing overreaches, and it's a leap the research itself doesn't make.
What you can do this week
- Treat "NAD+ declines with age" as established and "raising it fixes aging" as unproven — they're different claims with very different amounts of evidence behind them, and it's worth knowing which one any source is actually making.
- Ask your clinician about unexplained fatigue directly, rather than assuming it's "low NAD+." Fatigue has many causes, most unrelated to NAD+, and a clinical history is how you actually find out which one applies to you.
- If you're curious whether an NAD+ injection makes sense for you, that's a clinician's call. Pallas prescribes NAD+ injections when a US-licensed clinician decides it's appropriate for your health history and goals.
NAD+'s decline with age is one of the more consistently replicated findings in this corner of biology — two different research groups, two different tissues, the same direction of result. What's still unsettled is everything downstream of that finding: whether raising it back up changes anything that matters for your health, and for whom. Treating the first claim as fact and the second as an open question is the accurate way to read the evidence as it stands today.








